親環(huán)素A(CYPA)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)
Multiplex Assay Kit for Cyclophilin A (CYPA) ,etc. by FLIA (Flow Luminescence Immunoassay)
PPIA; CyP-A; CYPH; Peptidylprolyl Isomerase A; Peptidyl-Prolyl Isomerase A; Peptidyl-prolyl cis-trans isomerase A; Cyclosporin A-binding protein
(注:單次混測(cè)多因子不超過8個(gè)指標(biāo) )
- 編號(hào)LMA979Ra
- 物種Rattus norvegicus (Rat,大鼠) 相同的名稱,不同的物種。
- 實(shí)驗(yàn)方法雙抗夾心
- 反應(yīng)時(shí)長3.5h
- 檢測(cè)范圍0.08-80ng/mL
- 靈敏度最小可檢測(cè)劑量小于等于0.027 ng/mL.
- 樣本類型serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- 下載 英文說明書 中文說明書
- 規(guī)格 8指標(biāo)數(shù) 7指標(biāo)數(shù) 6指標(biāo)數(shù) 5指標(biāo)數(shù) 4指標(biāo)數(shù) 3指標(biāo)數(shù) 2指標(biāo)數(shù)1指標(biāo)數(shù)
- 價(jià)格 ¥ 2562 ¥ 2660 ¥ 2808 ¥ 3005 ¥ 3202 ¥ 3497 ¥ 3941 計(jì)算器 ¥ 4926 添加到價(jià)格計(jì)算器
- 欲了解實(shí)際交易價(jià)格和更多情況,請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
特異性
本試劑盒用于檢測(cè)親環(huán)素A(CYPA)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法),經(jīng)檢測(cè)與其它相似物質(zhì)無明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來源的限制,不可能完成對(duì)所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測(cè),因此本試劑盒有可能與未經(jīng)檢測(cè)的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的親環(huán)素A(CYPA)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)(加標(biāo)樣品),重復(fù)測(cè)定并計(jì)算其均值,回收率為測(cè)定值與理論值的比率。
樣本 | 回收率范圍(%) | 平均回收率(%) |
serum(n=5) | 90-101 | 97 |
EDTA plasma(n=5) | 82-96 | 90 |
heparin plasma(n=5) | 84-102 | 94 |
精密度
精密度用樣品測(cè)定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差:取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測(cè),每份樣本連續(xù)測(cè)定20 次,分別計(jì)算不同濃度樣本的平均值及SD值。
批間差:選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測(cè)定,每個(gè)樣本使用同一試劑盒重復(fù)測(cè)定8次,分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差: CV<10%
批間差: CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的親環(huán)素A(CYPA)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法),并倍比稀釋成1:2,1:4,1:8,1:16的待測(cè)樣本,線性范圍即為稀釋后樣本中親環(huán)素A(CYPA)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)含量的測(cè)定值與理論值的比率。
樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
serum(n=5) | 87-96% | 78-91% | 78-88% | 95-105% |
EDTA plasma(n=5) | 91-101% | 97-105% | 81-101% | 96-104% |
heparin plasma(n=5) | 80-103% | 97-104% | 84-92% | 85-92% |
穩(wěn)定性
經(jīng)測(cè)定,試劑盒在有效期內(nèi)按推薦溫度保存,其活性降低率小于5%。
為減小外部因素對(duì)試劑盒破壞前后檢測(cè)值的影響,實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致,尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本準(zhǔn)備;
2. 加樣(標(biāo)準(zhǔn)品、樣本、磁珠)標(biāo)準(zhǔn)品或樣本100μL及磁珠10μL,
37°C酶標(biāo)板振蕩器孵育90分鐘;
3. 磁吸甩干,加檢測(cè)溶液A100μL,37°C酶標(biāo)板振蕩器孵育60分鐘;
4. 磁吸洗板3次;
5. 加檢測(cè)溶液B100μL,37°C振動(dòng)孵育30分鐘;
6. 磁吸洗板3次;
7. 加鞘液100μL,旋渦震蕩2分鐘后讀數(shù)。
實(shí)驗(yàn)原理
將親環(huán)素A(CYPA)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)抗體包被于磁珠,制成固相載體,向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本以及磁珠,其中的親環(huán)素A(CYPA)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)與連接于固相載體上的抗體結(jié)合,然后加入生物素化的親環(huán)素A(CYPA)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)抗體,將未結(jié)合的生物素化抗體洗凈后,加入PE標(biāo)記的親和素,再次徹底洗滌后即可上機(jī)讀數(shù)。MFI值和樣品中的親環(huán)素A(CYPA)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)呈正相關(guān)。
贈(zèng)品
相關(guān)產(chǎn)品
編號(hào) | 適用物種:Rattus norvegicus (Rat,大鼠) | 應(yīng)用(僅供研究使用,不用于臨床診斷!) |
RPA979Ra01 | 親環(huán)素A(CYPA)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
PAA979Ra01 | 親環(huán)素A(CYPA)多克隆抗體 | WB; IHC; ICC; IP. |
LAA979Ra71 | 親環(huán)素A(CYPA)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
LAA979Ra81 | 親環(huán)素A(CYPA)多克隆抗體(異硫氰酸熒光素標(biāo)記) | WB; IHC; ICC; IF. |
MAA979Ra29 | 親環(huán)素A(CYPA)單克隆抗體 | WB; IHC; ICC; IP. |
MAA979Ra24 | 親環(huán)素A(CYPA)單克隆抗體 | WB; IHC; ICC; IP. |
MAA979Ra23 | 親環(huán)素A(CYPA)單克隆抗體 | WB; IHC; ICC; IP. |
MAA979Ra22 | 親環(huán)素A(CYPA)單克隆抗體 | WB; IHC; ICC; IP. |
MAA979Ra25 | 親環(huán)素A(CYPA)單克隆抗體 | WB; IHC; ICC; IP. |
MAA979Ra21 | 親環(huán)素A(CYPA)單克隆抗體 | WB; IHC; ICC; IP. |
MAA979Ra27 | 親環(huán)素A(CYPA)單克隆抗體 | WB; IHC; ICC; IP. |
SEA979Ra | 親環(huán)素A(CYPA)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
LMA979Ra | 親環(huán)素A(CYPA)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
PSA979Ra01 | 親環(huán)素A(CYPA)抗體對(duì) | ELISA; CLIA; ELISPOT; Luminex; Immunochromatography and other Immunoassays. |
KSA979Ra01 | 親環(huán)素A(CYPA)檢測(cè)試劑盒DIY材料(酶聯(lián)免疫吸附試驗(yàn)法) | Main materials for "Do It (ELISA Kit) Yourself". |
參考文獻(xiàn)
雜志 | 參考文獻(xiàn) |
Atherosclerosis | EMMPRIN and its ligand cyclophilin A regulate MT1-MMP, MMP-9 and M-CSF during foam cell formation [PubMed: 19758589] |
Biomarkers | Cyclophilin-A: a novel biomarker for untreated male essential hypertension [Pubmed: 24164594] |
Cardiovascular Diabetology | Plasma level of cyclophilin A is increased in patients with type 2 diabetes mellitus and suggests presence of vascular disease [Pubmed:24502618] |
International Journal of Biological Sciences | Decrease in Plasma Cyclophilin A Concentration at 1 Month after Myocardial Infarction Predicts Better Left Ventricular Performance and Synchronicity at 6 Months: A Pilot Study in Patients with ST Elevation Myocardial Infarction [Pubmed:25552928] |
Medicine | Cyclophilin A in Ruptured Intracranial Aneurysm [PubMed: 26426668] |
Mol Cell Biochem | PPIA rs6850: A> G single-nucleotide polymorphism is associated with raised plasma cyclophilin A levels in patients with coronary artery disease [PubMed: 26702934] |
Medicine (Baltimore) | Urinary Cyclophilin A as a New Marker for Diabetic Nephropathy: A Cross-Sectional Analysis of Diabetes Mellitus [PubMed: 26496315] |
International Journal of Cardiology | Cyclophilin?A?modulates?bone?marrow-derived?CD117(+)?cells?and?enhances?ischemia-induced?angiogenesisvia?the?SDF-1/CXCR4?axis. [Pubmed:27057951] |
Clinica?Chimica?Acta | Novel findings of secreted cyclophilin A in diabetic nephropathy and its association with renal protection of dipeptidyl peptidase 4 inhibitor [pubmed:27823952] |
Cardiovascular?Diabetology | Cyclophilin?A?enhances?macrophage?differentiation?and?lipid?uptake?in?high?glucose?conditions: a cellular mechanism for accelerated macro vascular disease in diabetes mellitus. [pubmed:27809851] |
Clinical?Science | Metformin attenuates effects of cyclophilin A on macrophages, reduces lipid uptake and secretion of cytokines by repressing decreased AMPK activity [Pubmed:29382697] |
Journal of Molecular Histology | Cyclophilin a increases CD68 cell infiltration in rat experimental periodontitis [Pubmed:29318411] |
Free?Radical?Research | Cyclophilin A and CD147 associate with progression of diabetic nephropathy [Pubmed: 30572748] |
The Kaohsiung Journal of Medical Sciences | Association of cyclophilin A level and pulse pressure in predicting recurrence of cerebral infarction [Pubmed: 31670477] |
Cells. | Cyclophilin A/EMMPRIN Axis Is Involved in Pro-Fibrotic Processes Associated with Thoracic Aortic Aneurysm of Marfan Syndrome Patients [Pubmed: 31936351] |
JAMA Neurology | APPENDIX A: Relationship between cyclophilin A levels and matrix metalloproteinase-9 activity in cerebrospinal fluid of cognitively normal apolipoprotein E4 carriers?… [Pubmed: 24030206] |
Menoufia Medical Journal | Urinary podocalyxin and cyclophilin A: markers for early detection of type 2 diabetic nephropathy [] |
Toxins | Evaluation of the Therapeutic Effects of Protocatechuic Aldehyde in Diabetic Nephropathy [34437430] |
Cell Death & Disease | Proteomic analysis reveals USP7 as a novel regulator of palmitic acid-induced hepatocellular carcinoma cell death [Pubmed:35732625] |